Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Elaine Soliven, 18 Sep 2020
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
Jairia Dela Cruz, 18 Feb 2020
Administering daily oral doses of adjunctive perampanel is safe and well tolerated in the treatment of young and older children with focal seizures or generalized tonic‐clonic seizures, in addition to yielding about 40–70 percent reduction in seizure frequency, according to data from the open-label 311 Core Study.

Veliparib regimen boosts PFS in women with advanced ovarian cancer

Elvira Manzano
03 Oct 2019
Dr Robert Coleman

Veliparib added onto frontline chemotherapy followed by veliparib maintenance monotherapy(veliparib throughout) significantly prolonged progression-free survival (PFS) in women with newly diagnosed high-grade serous ovarian carcinoma, the phase III placebo-controlled VELIA/GOG-3005 trial has shown.

Women treated with veliparib throughout achieved a significantly longer median PFS than women treated with chemotherapy alone (control group). “The benefit was observed in the full cohort regardless of BRCA mutation or homologies recombination deficiency (HRD) status,” said study author Dr Robert Coleman from the MD Anderson Cancer Centre in Houston, Texas, US. [ESMO 2019, abstract LBA3; N Engl J Med 2019;doi:10.1056/NEJMoa1909707)

In the intention-to-treat population, median PFS was 23.5 months with veliparib throughout vs 17.3 months for chemotherapy alone (hazard ratio [HR], 0.68, 95 percent confidence interval [CI], 0.56–0.83; p<0.001).

PARP* inhibitor added to chemo in VELIA

Veliparib, a PARP inhibitor, has demonstrated single-agent activity in recurrent germline BRCA1- or BRCA2-positive ovarian cancer. There have been interests in combining PARP inhibitors with cytotoxic chemotherapy for ovarian cancer treatment, but those efforts have been limited by unacceptable haematologic toxicity that often requires substantial dose reductions, said Coleman.

VELIA is the first phase III study to assess the impact of combination chemotherapy plus a PARP inhibitor. The study involved 1,140 women with previously untreated stage III or IV high-grade serous epithelial ovarian cancer, all of whom received first-line induction chemotherapy with carboplatin and paclitaxel. They had ECOG performance status 0–2, without  central nervous system metastases. Germline and tissue BRCA mutations and HRD were determined by central testing. Twenty-six percent of the patients had BRCA mutations and 55 percent  had HRD.

Patients were randomized to one of three groups: veliparib 150 mg twice daily added onto chemotherapy followed by veliparib 400 mg twice daily for 30 cycles as maintenance (veliparib-throughout, n=382), veliparib + chemotherapy followed by placebo for maintenance (veliparib combination only, n=383), or chemotherapy alone (control, n=375).

There was a significant benefit with veliparib-throughout regimen, but the independent value of adding veliparib to chemotherapy without veliparib maintenance was less clear, Coleman reported. Veliparib plus chemotherapy also led to a higher incidence of anaemia and thrombocytopenia, as well as nausea and fatigue, overall. But Coleman said the toxicities observed with veliparib were consistent with the known safety profile of veliparib.

Certain subgroups of patients derived greater benefits. To illustrate this point, median PFS in women with BRCA mutation was 34.7 months in the veliparib-throughout group vs 22 months in the control group (HR for progression or death, 0.44, 95 percent CI, 0.28–0.68; p<0.001). In patients with HRD, PFS was 31.9 and 20.5 months, respectively (HR 0.57, 95 CI, 0.43–0.76; p<0.001).

A new standard of care for newly diagnosed ovarian cancer?

The data regarding overall survival were not sufficiently mature in the BRCA-mutation cohort, the HRD cohort, and the ITT population, with percentages of required endpoints of 21 percent, 24 percent, and 49 percent, respectively. And because of the testing hierarchy, OS in the veliparib-throughout group vs the control group cannot be tested until a sufficient number of events have occurred, so formal hypothesis testing of PFS in the veliparib combination-only group vs the control group has not been performed, said Coleman.

“Still, we believe veliparib in combination with chemotherapy, and continued as maintenance, should be considered a new treatment option for women with newly diagnosed, advanced-stage serous ovarian cancer,” Coleman concluded.

“The time has come for all patients to have a PARP inhibitor,” said discussant Dr Mansoor Raza Mirza from the Rigshospitalet of Copenhagen University in Copenhagen, Denmark.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Elaine Soliven, 18 Sep 2020
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
Jairia Dela Cruz, 18 Feb 2020
Administering daily oral doses of adjunctive perampanel is safe and well tolerated in the treatment of young and older children with focal seizures or generalized tonic‐clonic seizures, in addition to yielding about 40–70 percent reduction in seizure frequency, according to data from the open-label 311 Core Study.